Rapid Dose TherapeuticsRDTCF -11.11%27 Gross Margin % is 47.32% as of Nov. 2025, which is 15% below its 10-year median of 55.90. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 729 Biotechnology companies, Rapid Dose Therapeutics ranks worse than 59.67% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Rapid Dose Therapeutics had a gross margin of 47.32% for the quarter that ended in Nov. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Rapid Dose Therapeutics Gross Margin % Related Terms
Rapid Dose Therapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDTCF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Rapid Dose Therapeutics (RDTCF) has a Gross Margin % of 47.32% as of Nov. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Rapid Dose Therapeutics and its competitors. This is 15% below median its historical median of 55.90. Over the past decade, Rapid Dose Therapeutics' Gross Margin % has ranged from 36.63 to 92.72. According to the industry distribution chart, Rapid Dose Therapeutics ranks #435 out of 729 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Rapid Dose Therapeutics' Gross Margin % too high?
Rapid Dose Therapeutics' current Gross Margin % of 47.32% is 15% below median its 10-year median of 55.90. Over the past 10 years, this metric has ranged from a low of 36.63 to a high of 92.72. The Biotechnology industry median Gross Margin % is 60.92. Rapid Dose Therapeutics' value of 47.32% is 22.3% below this industry median. Based on the distribution chart, Rapid Dose Therapeutics ranks #435 out of 729 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #435 out of 729 companies for Gross Margin %. This places Rapid Dose Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.92. Rapid Dose Therapeutics' value of 47.32% is 22.3% below this benchmark. Historically, Rapid Dose Therapeutics' own Gross Margin % has ranged from 36.63 to 92.72 over the past decade. While the company's 10-year median is 55.90 vs. the industry median of 60.92, Rapid Dose Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Dose Therapeutics's current Gross Margin % of 47.32% is 22.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Rapid Dose Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current Gross Margin % is 47.32%, which is 15% below median its own 10-year median of 55.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Gross Margin % is 47.32%, which is 15% below median its 10-year median of 55.90 and 22.3% below the Biotechnology industry median of 60.92. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Gross Margin % is 47.32% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
Gross Margin %: 47.32% (15% below median its 10-year median of 55.90)
GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
Industry Position: 22.3% below the Biotechnology median (#435 of 729)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score
Get the complete analysis for RDTCF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
